Evaluation of Safety and Tolerability of Salvia Haenkei Extract As a Dietary Supplement Ingredient

ConditionAging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-65
SponsorIBSA Farmaceutici Italia Srl

About this trial

Evalution of the safety and tolerability of the oral administration of Salvia haenkei in a healthy population.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Informed consent as documented by signature

Male or female

Age 55-65 years, inclusive

In good general health as evidenced by medical history and current health status

Disqualifiers

Body Mass Index < 18.5 or ≥ 30

Difficulty in swallowing (dysphagia)

Known allergy or sensitivity to any ingredient of the study intervention

Any medical condition or clinically significant abnormalities in laboratory values (hematology, blood chemistry, urinalysis) at screening which in the judgment of the Investigator makes the subject unsuitable for the study

Trial design

Design model

Parallel

Treatments tested in this trial

  • Salvia haenkei 175mg

    Dietary supplement

    The product appears as a soft gel containing the dry extract of Salvia haenkei

  • Salvia haenkei 350mg

    Dietary supplement

    The product appears as a soft gel containing the dry extract of Salvia haenkei

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Lower dose (175mg)Experimental treatment 1 intervention
Group B: Higher dose (350mg)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Occurrence of adverse events

Number of adverse events, serious adverse events, clinically significant changes in clinical laboratory assessments (hematology, chemistry, urinalysis) and clinically significant changes in vital signs or other clinical assessments will be evaluated.

Time frame
From Day 0 to Day 90
2

Tolerability assessment by evaluation of the number of subjects who will not withdraw prematurely from the study

Tolerability is defined as the number of subjects who will not withdraw prematurely from the study due to the occurrence of any AEs or SAEs.

Time frame
From Day 0 to Day 90

Secondary outcomes

1

Change from baseline of muscle strength assessed by grip test using the pneumatic dynamometer

Subjects will be asked to squeeze rubber balls (available in three sizes) three times for each side using the dominant hand. The best result of the 3 attempts will be taken into consideration.

Time frame
Day 0, Day 90
2

Change from baseline of muscle strength assessed by repeated chair stand test

Repeated chair stand test is a timed test requiring subjects to rise from a chair without using their arms and return to the seated position, consecutively, for five times. This test has been shown to be able to provide a reliable and valid indication of lower body strength. The cut-off is \> 15 seconds for five rises.

Time frame
Day 0, Day 90
3

Change from baseline of physical performance assessed by gait speed test

Gait speed test is used to assess walking speed in meters per second over a 4-metre distance at a comfortable pace. Subjects with a gait speed \<0.8 m/s are described as having a poor physical performance.

Time frame
Day 0, Day 90
4

Change from baseline of physical performance assessed by six minute walking test

The six minute walking test will assess functional exercise capacity. The test will measure the distance that a subject can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism.

Time frame
Day 0, Day 90

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.